
Lenacapavir for HIV Pre-Exposure Prophylaxis (PrEP)
Episode 21
In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly. She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects. You’ll also hear strategies to help patients overcome cost barriers, improve adherence, and understand the importance of regular follow-up. Whether you’re supporting patients at the pharmacy counter or staying current on HIV prevention, this episode delivers timely insights for pharmacy teams and other healthcare professionals. This is an excerpt from our September 2025 Pharmacy Essential Updates continuing education webinar series. ****** CE Information: TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.
Publisher
Clinical Capsules - Actionable Medication Pearls in Minutes
Published
November 25, 2025
Duration
16 min
Format
Podcast
Category
Lifestyle · Courses
Source
RSS feed
Host
TRC Healthcare | Pharmacist's Letter | Prescriber Insights | Pharmacy Technician's Letter
Clinical Capsules - Actionable Medication Pearls in Minutes
@clinicalcapsulesactionableme
#lenacapavir #hivpre #exposureprophylaxis #medicine #courses
